Has Ramiro Maldonado, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,999 in general payments to Ramiro Maldonado, MD across 27 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Ramiro Maldonado, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Ramiro Maldonado, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Ramiro Maldonado, MD

Ophthalmology · Durham, NCNPI 1215228036

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,276 and has fallen 78.5% since, to $275 in 2025.

$2,999in general payments, 2019–2025

Across 27 payments — averaging $111.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Regeneron$503
Insmed, Inc.$275
Bausch & Lomb Americas Inc.$231
Regeneron Healthcare Solutions, Inc.$224
Heidelberg Engineering, Inc.$205
Genentech, Inc.$199
plus $1K from 12 others

$7,832in research payments, 2019–2025

Across 5 payments — averaging $1566.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$8K

What the payments were for

Consulting fees$2759%
Food & beverage$2,72491%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Regeneron	5	$503
Insmed, Inc.	1	$275
Bausch & Lomb Americas Inc.	2	$231
Regeneron Healthcare Solutions, Inc.	2	$224
Heidelberg Engineering, Inc.	1	$205
Genentech, Inc.	2	$199
Spark Therapeutics, Inc.	2	$173
Coherus Oncology, Inc.	2	$168
Dutch Ophthalmic, USA	1	$150
Eyepoint US, Inc.	1	$134
Genentech USA, Inc.	1	$126
Rhythm Pharmaceuticals, Inc.	1	$125
Apellis Pharmaceuticals, Inc.	1	$108
AbbVie	1	$103
Ocular Therapeutix, Inc.	1	$93
Novartis	1	$89
Alcon	1	$61
Astellas Pharma US Inc	1	$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,999 in reported general payments places this provider in the 70th percentile of 588 ophthalmology providers in North Carolina.

See all ophthalmology providers in North Carolina →

Medicare billing

Part B allowed, 2024

$87,801

Medicare patients

238

Services billed

1,029

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ketorolac Tromethamine	13	$757
ErythromycinErythromycin Base	14	$167

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Durham

Julie WoodwardDurham$1M
Lejla VajzovicDurham$681K
Terry KimDurham$605K
Leon HerndonDurham$230K
Glenn JaffeDurham$218K
Robin VannDurham$213K
Anthony KuoDurham$186K
Michael RichardDurham$113K
Priyatham MettuDurham$111K
Jason LissDurham$69K

See the full list for North Carolina →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →